Clinical Trial

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out whether BMS986365 in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects for people who have localized high-risk prostate cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-09.
Trial Details
NCT Number NCT07335796
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Prostate Cancer
Enrollment 30 participants
Start Date 2026-01-09
Primary Completion 2030-01-09 (estimated)
Study Completion 2030-01-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-13